Latest News and Press Releases

Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...

Balixafortide shown to have synergistic or additive effect with conventional or targeted therapies across all tested B-cell lymphomas ALLSCHWIL, Switzerland, Dec. 13, 2022 (GLOBE NEWSWIRE) --...

Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support potential to use significantly higher doses of balixafortide...

Ad hoc announcement pursuant to Art. 53 LR Study start-up activities nearly complete for COPILOT, the first part of the Phase 3 ColiFin® program, including regulatory and ethics committee approvals...

ALLSCHWIL, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company...

Cash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide...

ALLSCHWIL, Switzerland, July 20, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company...

ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated...

ALLSCHWIL, Switzerland, May 19, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place May...

BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M pre-merger, convertible...